Repligen (NASDAQ:RGEN) Reaches New 12-Month Low – What’s Next?

Shares of Repligen Corporation (NASDAQ:RGEN) reached a new 52-week low during trading on Wednesday . The company traded as low as $109.44 and last traded at $111.1530, with a volume of 420094 shares trading hands. The stock had previously closed at $113.60.

Analyst Upgrades and Downgrades

RGEN has been the topic of several recent analyst reports. Jefferies Financial Group reissued a “hold” rating and issued a $142.00 target price on shares of Repligen in a report on Tuesday, May 5th. Roth Mkm initiated coverage on shares of Repligen in a research report on Friday, April 17th. They set a “buy” rating and a $160.00 price target on the stock. UBS Group decreased their price objective on shares of Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Rothschild & Co Redburn set a $160.00 target price on Repligen and gave the stock a “buy” rating in a research note on Friday, April 17th. Finally, Royal Bank Of Canada assumed coverage on Repligen in a report on Thursday. They issued an “outperform” rating and a $160.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and an average target price of $166.15.

Repligen Trading Up 0.3%

The business’s 50 day moving average price is $119.42 and its two-hundred day moving average price is $142.46. The company has a market capitalization of $5.85 billion, a price-to-earnings ratio of 115.21, a P/E/G ratio of 2.06 and a beta of 1.09. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The firm had revenue of $194.26 million for the quarter, compared to analyst estimates of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company’s quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter last year, the business posted $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, equities analysts predict that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Institutional Trading of Repligen

A number of hedge funds have recently made changes to their positions in RGEN. Measured Wealth Private Client Group LLC bought a new position in Repligen in the 3rd quarter valued at approximately $29,000. Bayforest Capital Ltd acquired a new position in Repligen in the 4th quarter valued at approximately $32,000. Rachor Investment Advisory Services LLC bought a new position in shares of Repligen during the fourth quarter valued at $33,000. Los Angeles Capital Management LLC bought a new position in shares of Repligen during the fourth quarter valued at $36,000. Finally, CWM LLC lifted its holdings in shares of Repligen by 67.2% during the third quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 135 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.